The drugmaker is facing pressure from investors to make purchases and licensing deals to ensure the long-term sustainability of its pharmaceutical division. This means having enough cash to buy new promising treatments from biotech firms to remain competitive.
Bayer is conducting a comprehensive review of its drug pipeline and is mulling tangible changes to cut expenses and simultaneously raise more cash to buy new therapies.
Bayer’s review will look at whether drug-testing services should be outsourced to cheaper entities. Labor representatives also are involved in the talks, according to the source familiar with the review.
Bayer has remained silent about potential cuts or outsourcing, declining Reuters‘ request for comments.
More articles on pharmacy:
Hospitals mark up drugs by 479%: 6 report findings
Narcan maker to be acquired by Emergent Biosolutions for $735M
US-Mexico trade deal grants drugmakers 10 years of patent exclusivity on biologics
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.